What to Know About GLP-1 Medications and Weight Management Programs
Learn how Eden connects patients to licensed providers to explore GLP-1 medications as part of medical weight management programs.
Learn how Contrave and semaglutide differ in their mechanisms, clinical use, and regulatory status. Understand how each is prescribed and what to consider when exploring medical weight management options with a licensed provider.
For individuals aiming to improve metabolic health and manage weight-related conditions, Prescription medications are being more frequently explored as part of provider-guided approaches to weight and metabolic health. Two common options, semaglutide and Contrave, offer different mechanisms of action and user experiences.
This guide outlines key differences between these FDA-approved medications, including mechanisms of action and published clinical data, to help patients better understand available options. While both may support weight-related outcomes, treatment decisions should always be made in consultation with a licensed medical provider based on individual health needs.
Note: Eden connects patients with independent, licensed medical providers who can assess to see whether or not you are an eligible candidate for medications.
Contrave is an FDA-approved oral weight management medication combining two drugs:
Together, these medications act on the hypothalamus and reward centers in the brain to help reduce food cravings and support appetite control.
Typical Use: Oral extended-release tablet, taken twice daily alongside lifestyle changes.
Common Side Effects:
Black Box Warning: Contrave includes a warning related to the risk of suicidal thoughts associated with bupropion, particularly in individuals with a history of depression or mood disorders. Providers may recommend psychiatric screening before prescribing (Christou & Kiortsis, 2015).
Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone involved in appetite and insulin regulation. It is the active ingredient in several FDA-approved medications, including::
In clinical studies and FDA-approved use, semaglutide has been shown to support metabolic health by:
Note: Semaglutide may help regulate appetite and promote healthier eating patterns when used as part of a provider-supervised plan.
In a 68-week clinical trial using an FDA-approved dose of semaglutide (2.4 mg weekly), participants with overweight or obesity lost an average of 14.9% of their body weight under structured medical and lifestyle supervision (Wen et al., 2024). (Wen et al., 2024).
Clinical studies on Contrave showed average weight reductions between 4% and 8%, depending on adherence and baseline characteristics (Padwal, 2009).
These results were observed under trial conditions involving intensive lifestyle support. Real-world outcomes may vary and should be discussed with a provider.
Semaglutide:
Contrave:
Semaglutide:
Contrave:
Both medications require gradual dose titration to reduce side effects and improve tolerability.
Note: Out-of-pocket costs vary by provider, location, and insurance plan. Eden providers can help explore affordability programs.
Semaglutide:
Contrave:
Your provider may recommend one medication over another based on:
Eden providers evaluate your health history to help personalize a plan using FDA-approved GLP-1 medications when appropriate.
Contrave and semaglutide are both FDA-approved options for weight management that work through different mechanisms and may be suited to different individuals. While semaglutide has been studied in trials with notable weight outcomes, Contrave may appeal to those who prefer an oral medication and are medically eligible.
The right approach depends on your health history, preferences, and provider guidance. Eden helps simplify the process by connecting you with licensed medical professionals who can evaluate your needs and determine whether a prescription is appropriate.
This content is for educational purposes only and does not constitute medical advice. Always speak with a qualified healthcare provider before starting or changing medications. Semaglutide and Contrave are FDA-approved for weight management under specific criteria. Use must follow a provider's clinical judgment and prescription. Eden connects users to licensed providers to assess whether or not you are an eligible candidate for GLP-1 medications. Eden is not a dispenser of any medication.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.